Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

SML0650

Sigma-Aldrich

Risedronate sodium

≥97% (HPLC)

Sinonimo/i:

P,P′-[1-Hydroxy-2-(3-pyridinyl)ethylidene]bis-phosphonic acid sodium, Sodium risedronate, [1-Hydroxy-2-(3-pyridinyl)ethylidene]bis[phosphonic acid] monosodium salt

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C7H10NO7P2 · Na
Numero CAS:
115436-72-1
Peso molecolare:
305.09
Codice UNSPSC:
41106300
NACRES:
NA.77

Saggio

≥97% (HPLC)

Forma fisica

powder

Colore

white to beige

Solubilità

H2O: 5 mg/mL, clear (warmed)

Temperatura di conservazione

room temp

InChI

1S/C7H11NO7P2.Na/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6;/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15);/q;+1/p-1
DRFDPXKCEWYIAW-UHFFFAOYSA-M

Azioni biochim/fisiol

Risedronate sodium is a bisphosphonate bone resorption inhibitor. It has an affinity for hydroxyapatite crystals in bone and acts as an antiresorptive agent and is an inhibitor of farnesyl diphosphate (FPP) synthase, which results in downstream inhibition of osteoclast activity and reduced bone resorption and turnover. Risedronate sodium has been used to treat postmenopausal osteoporosis and Paget′s disease.

Pittogrammi

Exclamation mark
GHS07

Avvertenze

Warning

Indicazioni di pericolo

H302 + H312 + H332

Classi di pericolo

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 9

1 of 9

USP

USP

1492801

Pamidronate disodium

Zoledronic acid monohydrate ≥98% (HPLC)

Sigma-Aldrich

SML0223

Zoledronic acid monohydrate

Alendronate sodium United States Pharmacopeia (USP) Reference Standard

USP

1012780

Alendronate sodium

Pamidronate, Disodium Salt A potent and specific inhibitor of bone resorption that does not cause any significant detrimental effect on bone growth and mineralization at concentrations used.

Sigma-Aldrich

506600

Pamidronate, Disodium Salt

(S)-CPP sodium salt ≥96% (HPLC)

Sigma-Aldrich

SML0804

(S)-CPP sodium salt

Alendronate sodium trihydrate ≥97% (NMR), powder

Sigma-Aldrich

A4978

Alendronate sodium trihydrate

Zoledronic Acid Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1893

Zoledronic Acid

USP

USP

1335417

Ibandronate sodium

vibrant-m

Y0000888

Clodronate disodium tetrahydrate

Y Sato et al.
Journal of musculoskeletal & neuronal interactions, 13(3), 346-352 (2013-08-31)
Minodronate is a nitrogen-containing bisphosphonate that is commercially available for the treatment of osteoporosis in Japan. Preclinical studies demonstrated that minodronate is at least 10 times more potent than alendronate in inhibiting bone resorption in vivo. A high incidence of
J B Matheny et al.
Bone, 57(1), 277-283 (2013-08-31)
Alterations in resorption cavities and bone remodeling events during anti-resorptive treatment are believed to contribute to reductions in fracture risk. Here, we examine changes in the size of individual remodeling events associated with treatment with a selective estrogen receptor modulator
Toshitaka Nakamura et al.
Calcified tissue international, 93(2), 137-146 (2013-05-07)
This randomized, double-blind study assessed the antifracture efficacy and safety of intermittent intravenous (IV) ibandronate versus oral daily risedronate in Japanese patients with primary osteoporosis. Ambulatory patients aged ≥60 years were randomized to receive 0.5 or 1 mg/month IV ibandronate
F L Gerritse et al.
European journal of cancer (Oxford, England : 1990), 49(15), 3176-3183 (2013-07-16)
Prostate cancer truly is an age-associated disease. Due to the increased life expectancy and more sensitive diagnostic techniques in the Western world, prostate cancer is diagnosed more frequently and with rapidly increasing incidence and prevalence rates. However, age above 65
J S Thomsen et al.
Scandinavian journal of rheumatology, 42(5), 408-416 (2013-03-27)
To investigate whether treatment with a bisphosphonate would influence the subchondral bone plate stiffness and the development of cartilage damage in Dunkin Hartley guinea pigs, which develop osteoarthritis (OA) spontaneously. Fifty-six 3-month-old male Dunkin Hartley guinea pigs were randomized into
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.